Bendamustine and rituximab: Complete response in a 62-year-old female with an aggressive lymphoma and an ejection fraction of 20%

Taha Alrifai*, Kelly Grant Szymanski, Parameswaran Venugopal, Brett Mahon, Tochukwu Okwuosa, Reem Karmali

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The treatment of diffuse large B-cell lymphoma in the presence of cardiac comorbidities can be challenging considering that the standard treatment regimen used for this aggressive subtype of non-Hodgkin lymphoma (NHL) consists of a combination of rituximab, cyclophosphamide, doxorubicin hydrochloride, Oncovin (vincristine), and prednisone (R-CHOP). The use of the anthracycline doxorubicin has been associated with arrhythmias and cardiomyopathy, making patients with cardiac dysfunction poor candidates for R-CHOP. As such, it is imperative to find alternative regimens that omit cardiac toxicity without compromising efficacy for this patient population. We report a case of composite NHL in a patient who received frontline bendamustine with rituximab with encouraging results. Our patient had a left ventricular ejection fraction of 20%, making her a poor candidate for anthracycline-based therapy. We opted to administer bendamustine with rituximab for a total of 6 cycles. She remains disease free 18 months after the completion of therapy.

Original languageEnglish (US)
Pages (from-to)140-146
Number of pages7
JournalChemotherapy
Volume62
Issue number2
DOIs
StatePublished - 2017

Keywords

  • Anthracycline
  • Bendamustine
  • Cardiac comorbidities
  • Non-Hodgkin lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Bendamustine and rituximab: Complete response in a 62-year-old female with an aggressive lymphoma and an ejection fraction of 20%'. Together they form a unique fingerprint.

Cite this